Data thru May 13, 2026
HomeTrendsArticlesDrug MarketsTherapeutic ClassesManufacturersPricingContact
Back to Market Feed

ARISTADA ER 662 MG/2.4 ML SYRN

aripiprazole lauroxil
$1000.6900per ML

Strength

662 mg/2.4mL

Manufacturer

Alkermes, Inc.

NDC

65757040203

Classification

Brand

Dosage Form

INJECTION, SUSPENSION, EXTENDED RELEASE

Route

INTRAMUSCULAR

Last Updated

1/1/2026

Active Ingredients

ARIPIPRAZOLE LAUROXIL

Approval Type

New Drug (NDA)

FDA Application

NDA207533

On Market Since

10/5/2015

Pharmacological Classes

Atypical Antipsychotic

Price History

1W

0.0%

1M

0.0%

3M

0.0%

6M

+5.9%

1Y

+6.4%

3Y

+11.6%

5Y

+18.4%

All

+52.7%

Generic Alternatives

No alternatives available

No alternatives found with the same active ingredient, strength, and dosage form.

Related Drugs

Same classification

SEROQUEL 25 MG TABLET
Brand
00310027510•AstraZeneca Pharmaceuticals LP
$3.7050
per EA
RISPERDAL 0.5 MG TABLET
Brand
50458030201•Janssen Pharmaceuticals Inc.
$4.3928
per EA
RISPERDAL 0.5 MG TABLET
Brand
50458030206•Janssen Pharmaceuticals Inc.
$4.3928
per EA
RISPERDAL 1 MG TABLET
Brand
50458030001•Janssen Pharmaceuticals Inc.
$4.6958
per EA
RISPERDAL 1 MG TABLET
Brand
50458030006•Janssen Pharmaceuticals Inc.
$4.6958
per EA
RISPERDAL 1 MG/ML SOLUTION
Brand
50458030503•Janssen Pharmaceuticals Inc.
$5.2507
per ML
SEROQUEL 50 MG TABLET
Brand
00310027810•AstraZeneca Pharmaceuticals LP
$6.0917
per EA
CLOZARIL 25 MG TABLET
Brand
69809012605•HLS Therapeutics (USA), Inc.
$6.2959
per EA
SEROQUEL 100 MG TABLET
Brand
00310027110•AstraZeneca Pharmaceuticals LP
$6.3802
per EA
SEROQUEL XR 50 MG TABLET
Brand
00310028060•AstraZeneca Pharmaceuticals LP
$7.7675
per EA

Data Source

Pricing data sourced from the National Average Drug Acquisition Cost (NADAC) survey, published by the Centers for Medicare & Medicaid Services (CMS). Updated weekly.

Disclaimer

This site is for informational purposes only and does not constitute medical, pharmaceutical, or financial advice. NADAC prices are survey-based estimates and may not reflect actual acquisition costs at any specific pharmacy.

Navigate

HomeAboutManufacturersDrug MarketsTherapeutic ClassesTrendsArticlesPricingContact

© 2026 NADAC Intelligence. All rights reserved. Not affiliated with CMS or any government agency.

Terms of ServicePrivacy Policy